CBG is short for cannabigerol. This cannabinoid is found early on in the growth cycle, which makes it somewhat difficult to find in large quantities. CBG, however, is non-psychoactive. This means that it can be cultivated via hemp. The medical potential of CBG makes it a prime target for research these days. Here’s what the science says so far:
Cannabigerol was another one of the cannabinoids tested on the MRSA virus in 2008. As far as antibiotic properties go, CBG was stronger than CBN and comparable to CBD. CBG is also known to be mildly anti-fungal. Research as early as 1982 found that isolated CBG is antimicrobial and kills various types of bacteria and fungi.
This cannabinoid just-so-happens to be good for your skin. Not only does it help prevent the reddening of the skin, but it’s been shown to have therapeutic potential for skin conditions like Psoriasis.
CBG is reportedly a more potent pain reliever than THC.
Back in 1998, Korean researchers found that CBG was effective at slowing the growth of cancerous cells in the mouth. More recent research published in the British Journal of Pharmacology found that CBG also had mild anti-tumor effects in prostate cancer cells. The study focused on non-THC cannabinoids. While CBG did have an effect on tumor growth, it was CBD that really shined through as a potential treatment for prostate cancer.
As early as 1975, researchers found that CBG prevented the uptake of amino acids that help regulate mood. The amino acid in question, GABA, was better regulated by CBG than THC or CBD.
Further studies have shown that CBG is a moderate anti-depressant, working to increase serotonin levels in your brain. The antidepressant effects of CBG were first found in 2006 in by Richard Musty and Richard Dayo who tests conducted on lab rats.